HOME     SUBSCRIBERS     TRADE     PRODUCTS & SERVICES    
About Sharenet
Enter any share name or code:    

12-Dec-2017
(Official Notice)
21-Nov-2017
(C)
21-Nov-2017
(Official Notice)
Life Healthcare shareholders are advised that the Company is in discussions regarding a potential transaction which, if successfully concluded, may have a material effect on the price of the Company?s shares. Accordingly, Life Healthcare shareholders are advised to exercise caution when dealing in their shares until a further announcement is made.

15-Nov-2017
(Official Notice)
The board of directors of Life Healthcare announced the appointment of Dr Shrey Viranna to the position of Group Chief Executive Officer and executive director of the company with effect from 1 February 2018.
13-Nov-2017
(Official Notice)
LifeHC is currently finalising the Group?s results for the year ended 30 September 2017. In this regard, shareholders are advised that the Company?s revenue, normalised EBITDA, earnings per share and headline earnings per share for the year ended 30 September 2017 are expected to vary by at least 20% from those reported in the prior comparative year ended 30 September 2016, as follows:



Estimated percentage range year ended 30 September 2017- estimated number range year ended 30 September 2017 - reported year ended 30 September 2016

* Revenue : +22.0% to +30.0% - R20 013m to R21 325m - R16 404m

* Normalised EBITDA : 13.0% to 21.0% - R4 875m to R5 220m - R4 314m

* Earnings per share (cents) : -52.0% to -60.0% - 69.2 to 57.6 - 144.1

* Headline earnings per share : -52.0% to -60.0% - 86.0 to 71.6 - 179.1



The Company expects to release its financial results for the year ended 30 September 2017 on the Stock Exchange News Service on or about 21 November 2017.
26-Jul-2017
(Official Notice)
In compliance with the JSE Limited Listings Requirements, the following information is disclosed:

The board is pleased to announce that Pieter van der Westhuizen in his capacity as acting CEO has been appointed as a member of the Clinical Governance, Quality and Safety Committee and the Social, Ethics and Transformation Committee with effect from 26 July 2017.
11-Jul-2017
(Official Notice)
The board announced that Adv. Mahlape Sello has been appointed as a member of the risk and remuneration and human resources committees with effect from 4 July 2017. Audrey Mothupi has been appointed as a member of the audit and risk committees with effect from 4 July 2017.



As Prof Marian Jacobs has assumed the chair of the newly established clinical governance and safety committee, she will no longer serve as a member of the remuneration and human resources committee with effect from 4 July 2017.
03-Jul-2017
(Official Notice)
The board announces that Adv. Mahlape Sello and Ms Audrey Mothupi have been appointed as independent non-executive directors of the Company with effect from 3 July 2017.





03-Jul-2017
(Official Notice)
29-Jun-2017
(Official Notice)
Shareholders are referred to the company?s unaudited interim financial results for the six months ended 31 March 2017, published on the Stock Exchange News Service (?SENS?) on 12 May 2017 and in the press on 15 May 2017, in which it declared an interim Scrip Distribution with the alternative to elect to receive a Cash Dividend of 35 cents per ordinary Life share.



The ratio applicable to the Scrip Distribution entitlement was announced on SENS on 20 June 2017, being 1.32772 Scrip Distribution shares for every 100 ordinary Life shares held on the Record Date, being Friday, 30 June 2017.



If the application of this ratio gives rise to a fraction of an ordinary Life share, such fraction will be rounded down to the nearest whole number, resulting in allocations of whole ordinary Life shares and a cash payment for the fraction (?Rounding Provision?).



In accordance with the requirements of the JSE Ltd., the cash payment has been determined with reference to the volume weighted average price of an ordinary Life share traded on the JSE on Wednesday, 28 June 2017 (being the day on which an ordinary Life share began trading ?ex? the entitlement to receive the Scrip Distribution or Cash Dividend alternative), discounted by 10%.



Shareholders are accordingly advised that the basis applicable in determining the cash payment for the fractional entitlement is 2314.36452 cents (2571.51613 cents, discounted by 10%) or 1851.49162 cents, net of applicable dividend withholding tax.



Example of fractional entitlement:

This example assumes that a Shareholder holds 100 ordinary Life shares at the close of business on the Record Date and does not elect to receive the Cash Dividend in respect of all or part of their shareholding.



New ordinary share entitlement = 100 x 1.32772% = 1.32772 new ordinary shares. The Rounding Provision described above is then applied and the shareholder will receive: 1 Scrip Distribution share in respect of the 100 ordinary shares held and a cash payment for the fractional entitlement of 0.32772 x 2314.36452 = 758.46354 cents. This fractional entitlement payment will be subject to 20% dividend withholding tax, resulting in a net cash payment of 606.77083 cents.
20-Jun-2017
(Official Notice)
12-Jun-2017
(Official Notice)
The board of directors of LifeHC ("the Board") announced that after three years as Chief Executive Officer ("CEO") of LifeHC, the board and Andr? Meyer have decided that he will step down as CEO and as a member of the Board with effect from 30 June 2017.



The Board has appointed Pieter van der Westhuizen, the current Chief Financial Officer ("CFO"), as the acting CEO. The recruitment process to find a suitable CEO with relevant experience has commenced.
05-Jun-2017
(Official Notice)
12-May-2017
(Official Notice)
The board announced that at a board meeting held on 11 May 2017, it was resolved to establish a Cinical Governance, Quality and Safety Committee as a board sub-committee with immedicate effect.



The following board members have been appointed to the Cinical Governance, Quality and Safety Committee:

- Prof. Marian Jacobs (Chairman) ? Independent non-executive

- Dr Malefatsane Peter Ngatane - Independent non-executive

- Mr Andr? Meyer ? Executive
12-May-2017
(C)
03-May-2017
(Official Notice)
Further to the announcement released on the Stock Exchange News Service (?SENS?) of the JSE Ltd. on 5 April 2017, and leading up to the interim results release on or around 12 May 2017, the company is able to provide additional clarity on the estimated results for the six months ended 31 March 2017. Shareholders are therefore advised that the previously estimated reversal of contingent consideration (income) related to the acquisition of Alliance Medical of between R180 million ? R220 million will change to an estimated expense of R12million ? R20million as a result of Alliance Medical performing better than anticipated and signing six Community Diagnostic Centre contracts, two more than the initial estimate of four contracts. This will result in an estimated GBP21 million of the contingent consideration being payable. The fair value of the GBP40 million contingent consideration at acquisition was estimated at GBP20 million. The final amount will be subject to audit and is a non- trading related item.



The Group updated estimated results for the six months ended 31 March 2017 are as follows:

Measure, Estimated Range, Six months ended 31 March 2017 (As communicated 5 April 2017), Estimated Range, Six months ended 31 March 2017 and Six months ended 31 March 2016 (Updated)

*Normalised EBITDA - +11% to +15%; R2 330m to R2 414m; +13.5% to +17.5%; R2 382m to R2 466m; R2 099m

*Earnings per share (cents) - -60% to -70%; 37.2 to 27.9; -80% to -90%; 18.6 to 9.3; 93.0

*Headline earnings per share (cents) - -50% to -60% 46.5 to 37.2 -70% to -75% 27.9 to 23.3 93.0



Headline earnings per share for the six months ended 31 March 2017 will also be impacted by the updated contingent consideration and is estimated to be between 23.3 cps and 27.9 cps, a movement of between a decline of 75% and 70.0% below the headline earnings per share for the six months ended 31 March 2016 of 93.0 cps.



The company expects to release its interim financial results for the six months ended 31 March 2017 on SENS on or about 12 May 2017.
18-Apr-2017
(Official Notice)
05-Apr-2017
(Official Notice)
28-Mar-2017
(Official Notice)
Further to the rights offer finalisation announcement (?Finalisation Announcement?) released on SENS on 23 March 2017 and published in the press on 24 March 2017, Life Healthcare confirms that the rights offer circular will be published on Life Healthcare?s website (www.lifehealthcare.co.za), today 28 March 2017 and will be posted to qualifying certificated shareholders on 30 March 2017. Where applicable, the rights offer circular will be posted to qualifying dematerialised shareholders on 4 April 2017.



With reference to the current trading commentary set out in the Finalisation Announcement and the rights offer circular, Life Healthcare shareholders are advised that the company expects to have greater clarity regarding the matters set out in the trading update and intends to release an announcement in relation thereto on or about 4 April 2017 including a trading statement if required.
23-Mar-2017
(Official Notice)
16-Mar-2017
(Official Notice)
26-Jan-2017
(Official Notice)
At the 12th annual general meeting (?AGM?) of the shareholders of Life Healthcare held on 25 January 2017, all the ordinary and special resolutions proposed at the meeting were approved by the requisite majority of votes.
25-Jan-2017
(Official Notice)
Shareholders are advised that Ms Louisa Mojela has resigned as a non-executive director of the company with effect from 25 January 2017. Ms Mojela has been a board member since June 2010.



The board is pleased to announce that following the resignation of Ms Mojela, Mpho Elizabeth Nkeli has been appointed as chairman of the social, ethics and transformation committee with effect from 25 January 2017 and Peter John Golesworthy as a member of the social, ethics and transformation committee with effect from 25 January 2017.



Ordinary resolution 3.2 of the notice of annual general meeting, proposes that LM Mojela be appointed as a member of the Group audit committee. As a result of her resignation, this resolution has now been withdrawn.



Shareholders are requested to disregard this resolution when voting at the company?s annual general meeting to be held on 25 January 2017.
20-Jan-2017
(Official Notice)
Life Healthcare shareholders are referred to the SENS announcements dated 16 November 2016 and 20 December 2016, wherein Life Healthcare announced the acquisition of Alliance Medical Group Ltd. (?Alliance Medical?) and a proposed renounceable rights offer (?Rights Offer?) to refinance a portion of the acquisition bridge facility.



Following further engagement and consultation with Life Healthcare shareholders, the board of directors (?Board?) has determined that the Company will seek to raise R9.0 billion through the Rights Offer. The Board believes that this proposed equity capital raising balances the views expressed by shareholders regarding the Company?s net debt position, financial flexibility and ability to continue paying dividends going forward.



The implementation of the proposed Rights Offer is subject to the approval of Life Healthcare shareholders at the annual general meeting to be held on 25 January 2017. The resolutions required to be passed in order to undertake the Rights Offer (being ordinary resolution number 5 and special resolutions number 1 and 6) will accordingly be proposed with the modification that the Rights Offer is subject to a maximum amount of R9.0 billion and not R10.7 billion as previously envisaged. The final terms of the Rights Offer will be announced as soon as practicable after the annual general meeting.
12-Jan-2017
(Official Notice)
20-Dec-2016
(Official Notice)
19-Dec-2016
(Official Notice)
Shareholders are referred to the Company?s audited financial results for the year ended 30 September 2016, released on the Stock Exchange News Service (?SENS?) on 11 November 2016 (?Results Announcement?), in which they were advised that Life?s board of directors had resolved to declare a final Scrip distribution of ordinary Life shares, incorporating the entitlement to elect to receive instead a Cash Dividend of 92 cents per ordinary Life share.



The ratio applicable to the Scrip Distribution entitlement was announced on SENS on 5 December 2016, being 2.96728 Scrip Distribution shares for every 100 ordinary Life shares held on the Record Date, being Thursday,15 December 2016.



If the application of this ratio gives rise to a fraction of an ordinary Life share, such fraction of a new ordinary Life share will be rounded down to the nearest whole number, resulting in allocations of whole ordinary Life shares and a cash payment for the fraction.



In terms of the Scrip Distribution, 15 792 914 new ordinary shares were issued to Shareholders who did not elect to receive the Cash Dividend in respect of all or part of their shareholding, resulting in a capitalisation of the distributable retained profits of the Company of R489 686 067.80. Shareholders recorded in the register of the Company at the close of business on the Record Date holding 525 532 556 ordinary shares elected to receive the gross Cash Dividend of 92 cents per ordinary share, resulting in a total gross Cash Dividend of R483 489 951.52 which was paid out of the distributable retained profits of the Company. Share certificates, where applicable, were dispatched to certificated Shareholders at their own risk, and the Cash Dividend payments were made/Central Securities Depository Participant/broker accounts of dematerialised Shareholders were credited on 19 December 2016.
05-Dec-2016
(Official Notice)
23-Nov-2016
(Official Notice)
16-Nov-2016
(Official Notice)
11-Nov-2016
(C)
11-Nov-2016
(Official Notice)
Life Healthcare shareholders are advised that the Company is in discussions regarding a potential acquisition. Accordingly, Life Healthcare shareholders should exercise caution when dealing in their shares until a further announcement is made.
21-Oct-2016
(Official Notice)
Further to the announcement released on the Stock Exchange News Service of the JSE Ltd. on 22 July 2016, shareholders are advised that the impact of the reduction in tariffs in Poland on the operations has been determined. This will result in an impairment of approximately R370 million to the carrying value of the investment in Poland in the Group?s results for the year ended 30 September 2016. The Group is reviewing its cost base and continues to drive integration efficiencies in the business to mitigate the impact of the tariff reductions.



As a consequence of the impairment, Life Healthcare?s earnings per share (?EPS?) for the year ended 30 September 2016 will be between 145cps and 160cps, a decline of between 19.4% and 11.1% below the earnings per share for the year ended 30 September 2015 of 179.9cps.



Headline earnings per share (?HEPS?) for the year ended 30 September 2016 will be between 180cps and 200cps, a growth of between 0.1% and 11.2% above the headline earnings per share for the year ended 30 September 2015 of 179.9cps.



The financial information on which this trading update is based has not been reviewed and reported on by the Company?s external auditors.



The Company expects to release its annual financial results for the year ended 30 September 2016 on SENS on or about 11 November 2016.





22-Jul-2016
(Official Notice)
Life through its subsidiaries has invested R2.1 billion in its Polish operation, Scanmed S.A. (?Scanmed?). The majority of Scanmed?s revenue is currently derived from contracts with the National Health Fund (NFZ) in Poland. The NFZ has announced updated tariffs in respect of cardiology procedures. This medical discipline accounts for approximately 45% of Scanmed?s revenue. The impact to Scanmed of the updated tariffs is on average a reduction of 20%, effective 1 July 2016. This change in tariffs will not have a material impact on the Group?s operating result for the 2016 financial year.



The Agency for Health Technology Assessment and Tariff System (AOTMiT) has proposed further changes that are to come into effect on 1 January 2017 for certain procedures in the orthopaedics and neurology disciplines. The impact of these proposed changes is immaterial.



Scanmed is in the process of establishing the impact of the reduction in tariffs on the operations as well as the corrective actions to be taken to mitigate the impact. The reduction in the regulated tariffs will likely result in an impairment to the carrying value of the investment in Poland in the Group?s results to 30 September 2016, the quantum of which is still to be determined. The impairment is not anticipated to exceed R380 million. Once certainty is achieved on the quantum, a further announcement will be released. The Group will continue to drive integration efficiencies in the business and will put further acquisitions on hold until clarity around tariffs is obtained.



Scanmed announced the appointment of Hubert Bojdo as CEO of Scanmed with effect from 1 July 2016 following the resignation from the Management Board of Joanna Szyman.
20-Jun-2016
(Official Notice)
Shareholders are referred to the company?s unaudited interim financial results for the six months ended 31 March 2016, released on the Stock Exchange News Service (?SENS?) on 11 May 2016, in which they were advised that Life?s board of directors had resolved to declare an interim Scrip Distribution of ordinary Life shares, incorporating the entitlement to elect to receive instead a Cash Dividend of 73 cents per ordinary Life share.



The ratio applicable to the Scrip Distribution entitlement was announced on SENS on 2 June 2016, being 1.97479 Scrip Distribution shares for every 100 ordinary Life shares held on the Record Date, being Friday, 17 June 2016.



If the application of this ratio gives rise to a fraction of an ordinary Life share, such fraction of a new ordinary Life share will be rounded down to the nearest whole number, resulting in allocations of whole ordinary Life shares and a cash payment for the fraction.



In terms of the Scrip Distribution, 9 338 588 new ordinary shares were issued today, 20 June 2016, to Shareholders who did not elect to receive the Cash Dividend in respect of all or part of their shareholding, resulting in a capitalisation of the distributable retained profits of the company of R345 209 872.92. Shareholders recorded in the register of the company at the close of business on the Record Date holding 575 571 196 ordinary shares elected to receive the gross Cash Dividend of 73 cents per ordinary share, resulting in a total gross Cash Dividend of R420 166 973.08 which was paid out of the distributable retained profits of the company. Share certificates, where applicable, were dispatched to certificated Shareholders at their own risk, and the Cash Dividend payments were made/Central Securities Depository Participant/broker accounts of dematerialised Shareholders were credited, today.
13-Jun-2016
(Official Notice)
Shareholders are referred to the company?s unaudited interim financial results for the six months ended 31 March 2016, released on the Stock Exchange News Service (?SENS?) on 11 May 2016, in which they were advised that Life?s board of directors had resolved to declare an interim scrip distribution of ordinary Life shares, incorporating the entitlement to elect to receive instead a cash dividend of 73 cents per ordinary Life share.



The ratio applicable to the scrip distribution entitlement was announced on SENS on 2 June 2016, being 1,97479 Scrip Distribution shares for every 100 ordinary Life shares held on the Record Date, being Friday, 17 June 2016.



If the application of this ratio gives rise to a fraction of an ordinary Life share, such fraction of a new ordinary Life share will be rounded down to the nearest whole number, resulting in allocations of whole ordinary Life shares and a cash payment for the fraction.



In accordance with the requirements of the JSE Ltd, the cash payment has been determined with reference to the volume weighted average price of an ordinary Life share traded on the JSE on Friday, 10 June 2016 (being the day on which an ordinary Life share began trading ?ex? the entitlement to receive the scrip distribution or cash dividend alternative), discounted by 10%.



Shareholders are accordingly advised that the applicable cash payment per fractional entitlement is 3239 cents.



Example of Scrip Distribution entitlement:

This example assumes that a Shareholder holds 100 ordinary shares at the close of business on the Record Date and does not elect to receive the cash dividend in respect of all or part of their shareholding.



New ordinary share entitlement = 100 x 1,97479% = 1,97479 new ordinary shares

(then apply the Rounding Provision described above) = 1 Scrip Distribution share in respect of the 100 ordinary shares held and 3239 cents for the fraction.



02-Jun-2016
(Official Notice)
11-May-2016
(C)
28-Jan-2016
(Official Notice)
At the 11th annual general meeting of the shareholders of LifeHC held on 27 January 2016, all the ordinary and special resolutions proposed at the meeting were approved by the requisite majority of votes.
18-Dec-2015
(Official Notice)
Shareholders are advised that the summarised consolidated annual financial results contained in the notice of annual general meeting will be distributed to shareholders on Friday, 18 December 2015 and contain no modifications to the audited results which were published on SENS on Friday, 13 November 2015. The integrated report will be available on the Life Healthcare website at www.lifehealthcare.co.za on Friday, 18 December 2015.



Notice of the annual general meeting

Notice is hereby given that the annual general meeting of the Company will be held at The Wanderers Club, 21 North Street, Illovo, Johannesburg on Wednesday, 27 January 2016 at 15h30 to transact the business as stated in the annual general meeting notice.



Salient dates

The notice of the Company?s annual general meeting has been sent to its shareholders who were recorded as such in the Company?s securities register on Friday, 11 December 2015 being the notice record date set by the Board of the Company used to determine which shareholders are entitled to receive notice of the annual general meeting.



Salient dates

*Record date to determine which shareholders are entitled to receive the notice of annual general meetingFriday, 11 December 2015

*Last day to trade in order to be eligible to attend and vote at the annual general meeting Friday, 15 January 2016

*Record date to determine which shareholders are entitled to attend and vote at the annual general meeting Friday, 22 January 2016

*Forms of proxy for the annual general meeting to be lodged by 15h30 Monday, 25 January 2016

*any proxies not lodged by this time may be handed to the chairman of the annual general meeting immediately prior to the appointed proxy exercising any of the shareholder rights at the annual general meeting.
14-Dec-2015
(Official Notice)
Shareholders are referred to the company?s audited financial results for the year ended 30 September 2015, released on the Stock Exchange News Service (?SENS?) on 13 November 2015 (?Results Announcement?), in which they were advised that Life?s board of directors had resolved to declare a final distribution of fully- paid Life ordinary shares of R0.000001 (?the Scrip Distribution?) to ordinary Shareholders (?Shareholders?) recorded in the register of the company at the close of business on the Record Date, being Friday, 11 December 2015.



As set out in the announcement, Shareholders not electing to receive the Cash Dividend in respect of all or part of their shareholding were entitled to receive that number of Scrip Distribution Shares determined in the ratio of 2.33882 Scrip Distribution shares for every 100 ordinary shares held on the Record Date. Where a Shareholder?s entitlement to Scrip Distribution Shares, calculated in accordance with the above ratio, gave rise to a fraction of a new ordinary share, such fraction of a new ordinary share was rounded up to the nearest whole number where the fraction was greater than or equal to 0,5 and rounded down to the nearest whole number where the fraction was less than 0.5.



In terms of the Scrip Distribution, 6 251 683 new ordinary shares were issued today to Shareholders who did not elect to receive the Cash Dividend in respect of all or part of their shareholding, resulting in a capitalisation of the distributable retained profits of the company of R229 876 466.70. Shareholders recorded in the register of the company at the close of business on the Record Date holding 774 911 533 ordinary shares elected to receive the gross Cash Dividend of 86 cents per ordinary share, resulting in a total gross Cash Dividend of R666 423 918.38, which was paid out of the distributable retained profits of the company. Share certificates, where applicable, were dispatched to certificated Shareholders at their own risk, and the Cash Dividend payments were made/Central Securities Depository Participant/broker accounts of dematerialised Shareholders were credited, today, 14 December 2015.
27-Nov-2015
(Official Notice)
19-Nov-2015
(Official Notice)
13-Nov-2015
(C)
12-Nov-2015
(Official Notice)
The board announced that following the appointment of Mpho Elizebeth Nkeli to the board with effect from 1 November 2015, Mpho has been appointed as a member of the social, ethics and transformation committee and the remuneration and human resources committee with effect from 12 November 2015. Joel Netshitenzhe will step down as a member of the social, ethics and transformation committee with effect from 12 November 2015 as he agreed to serve on the committee as an interim measure until a new board member was appointed.
15-Sep-2015
(Official Notice)
The board is pleased to announce that Mpho Nkeli has been appointed as an independent non-executive director of the Company with effect from 1 October 2015.

13-May-2015
(C)
Revenue increased by 14.1% to R7.1 billion (R6.2 billion). Operating profit decreased by 33.8% to R1.6 billion (R2.5 billion). Net attributable profit decreased by 54.1% to R832 million (R1.8 billion). In addition, headline earnings per lowered by 2.9% to 80.3cps (82.7cps).



Dividend

The directors approved an interim gross cash dividend of 68 cents per ordinary share (2014: 63 cents per ordinary share) for the six months ending 31 March 2015.



Outlook

LifeHC will continue to focus on its growth objectives in southern Africa, India and Poland. Over 170 new beds will be added in southern Africa in the next six months through 80 brownfield expansion beds and the addition of the 94 bed Life Hilton Private Hospital.



LifeHC's proposed acquisition of the 50 bed Lowveld Hospital has been terminated as per the seller's wishes, due to the slow approval process of the

Competition authorities.



Max will continue to grow revenue and improve EBITDA margins and is well positioned to take advantage of the rapidly developing private healthcare sector in India, leveraging off the existing base and growing by brownfield expansions, greenfield projects and through acquisitions.



In Poland LifeHC will continue to execute on its strategy of establishing a comprehensive network of facilities through the integration of the existing businesses, positioning the business to maximise growth in new national health contracts in 2016 and through exploring new acquisition opportunities.



In southern Africa, the pressure on costs will remain in light of the weakening of the rand exchange rate, wage expectations and other overhead costs but LifeHC will continue to focus on efficiency programmes to lessen the impact.



The quality management programme of LifeHC is a comprehensive, consistently applied and measured programme which benchmarks clinical interventions against international best practice with the aim of enhancing patient outcomes. In addition Life Healthcare recognises the shortage of healthcare skills and will continue to invest heavily in the training of doctors, nurses and pharmacists. The Competition Commission Market Inquiry into the healthcare sector will continue during the remainder of 2015.
03-Feb-2015
(Official Notice)
Shareholders are advised that Life Healthcare?s earnings per share for the six months ending 31 March 2015 are expected to show a decrease of between 65 and 100 cents per share or between 37.2% and 57.2% from that reported for the six months ended 31 March 2014 (174.8 cents per share). This expected decrease is largely due to Life Healthcare?s disinvestment of its 49.3% shareholding in Joint Medical Holdings Limited in the prior year.



The forecast financial information on which this trading statement is based has not been reviewed and reported on by the Company?s external auditors.

03-Feb-2015
(Official Notice)
In compliance with the JSE Ltd. Listings Requirements, the following information is disclosed:



The board is pleased to announce that following the retirement of Adv. Fran du Plessis at the Annual General Meeting of the Company held on 28 January 2015, Garth Solomon has been appointed as a member of the audit committee with effect from 29 January 2015 and Joel Netshitenzhe as a member of the social, ethics and transformation committee with effect from 29 January 2015.



Garth holds a BCom, BCompt(Hons) and is a CA. He has served in various commercial and corporate financial roles and is currently the co-owner and director of Evolve Capital.



Joel holds an MSc, in addition to a postgraduate diploma in Economic Principles and a diploma in political science. He is currently the executive director and vice chairman of the board of the Mapungubwe Institute for Strategic Reflection.
29-Jan-2015
(Official Notice)
At the 10th annual general meeting of the shareholders of LifeHC held on 28 January 2015, all the ordinary and special resolutions proposed at the meeting were approved by the requisite majority of votes, save for ordinary resolution number 4, Approval of the remuneration policy of the company.
12-Dec-2014
(Official Notice)
Shareholders are advised that the summarised consolidated annual financial results contained in the notice of annual general meeting will be distributed to shareholders on Friday, 12 December 2014 and contain no modifications to the audited results which were published on SENS on Friday, 13 November 2014. The integrated annual report will be available on the Life Healthcare website at www.lifehealthcare.co.za on Friday, 12 December 2014.



Notice of the annual general meeting

Notice is hereby given that the annual general meeting of the company will be held at The Wanderers Club, 21 North Street, Illovo, Johannesburg on Wednesday, 28 January 2015 at 15h30 to transact the business as stated in the annual general meeting notice.



Salient dates

The notice of the company's annual general meeting has been sent to its shareholders who were recorded as such in the company's securities register on Friday, 5 December 2014 being the notice record date set by the board of the company used to determine which shareholders are entitled to receive notice of the annual general meeting.



Salient dates

*Record date to determine which shareholders are entitled to receive the notice of annual general meeting -- Friday, 5 December 2014

*Last day to trade in order to be eligible to attend and vote at the annual general meeting -- Friday, 16 January 2015

*Record date to determine which shareholders are entitled to attend and vote at the annual general meeting -- Friday, 23 January 2015

*Forms of proxy for the annual general meeting to be lodged by 15h30* -- Monday, 26 January 2015



*any proxies not lodged by this time may be handed to the chairman of the annual general meeting immediately prior to the appointed proxy exercising any of the shareholder rights at the annual general meeting.
17-Nov-2014
(Media Comment)
Business Day reported that LifeHC has entered into discussions to acquire two businesses in Poland. CEO Andre Meyer said the group was in the final stages of acquiring a 46-bed ortopaedic hospital, and was doing due-diligence research with a view to buying a leading healthcare provider in Poland. "There's an exceptional potential for us to grow in Poland," Mr Meyer commented.
14-Nov-2014
(C)
Revenue for the year went up 10.2% to R13.0 billion (R11.8 billion). Operating profit shot up 42.4% to R4.1 billion (R2.9 billion). Profit attributable to equity holders jumped 62.1% to R2.8 billion (R1.7 billion). In addition, headline earnings per share were 7.9% higher at 177.8 cents per share (164.8 cents per share).



Cash dividend declaration

The directors approved a final gross cash dividend of 78 cents per ordinary share (72 cents per ordinary share) for the year ended 30 September 2014. The dividend has been declared from income reserves and no secondary tax on companies' credits have been utilised.



Outlook

The Group will continue to focus on its growth objectives in southern Africa, India and Poland. Over 250 new beds will be added in 2015 through the opening of Life Hilton Private Hospital and through brownfield expansion. The complementary services line will grow by adding more than 30 renal dialysis stations in the next year.



Max will focus on growing revenue and improving operational efficiencies. It will also continue to operationalise the beds not yet active and is in advanced stages of further brownfield expansions.



In Poland the Group will continue to execute on its strategy of establishing a comprehensive network of facilities and will explore more acquisition opportunities.



The pressure on costs will remain in light of the weakening of the Rand exchange rate, wage expectations and other overhead costs but the Group will continue to focus on efficiency programmes to lessen the impact.



The Group concluded the Max equalisation on 10 November 2014 and now owns 46.25% of the business. The additional amount invested was R1.35 billion.



The quality management programme of the Group is a comprehensive, consistently applied and measured programme which benchmarks clinical interventions against international best practice with the aim of enhancing patient outcomes. In addition Life Healthcare recognises the shortage of healthcare skills and will continue to invest heavily in the training of doctors, nurses and pharmacists. The Competition Commission Market Inquiry into the healthcare sector will continue into 2015. The Inquiry represents an opportunity to factually demonstrate what the real cost drivers of the healthcare industry are as well as proposing structural changes to make the industry more efficient and affordable and we will participate fully.
27-Oct-2014
(Official Notice)
Further to the trading statement released on the Stock Exchange News Service of the JSE Ltd. on 12 May 2014 as part of the interim results announcement, shareholders are advised that LifeHC's earnings per share ("EPS") for the year ended 30 September 2014 will be between 260cps and 270cps, a growth of between 57% to 63% above the restated earnings per share for 2013 of 164.8cps.



This increase is largely due to the profit arising on LifeHC's disinvestment of its 49.3% shareholding in Joint Medical Holdings Limited in February 2014.



Headline earnings per share ("HEPS") for the year ended 30 September 2014 will be between 170cps to 180cps, a growth of between 3% to 9% above the restated headline earnings per share of 164.8cps.



The directors believe that normalised earnings per share from continuing operations best reflect the performance of the Company and expect that normalised earnings per share* will be 8% to 14% greater than those reported in the comparative period.



*Excludes profit/loss on disposals of businesses as well as excluding non-trading related items and the effect of discontinued businesses. The discontinued businesses contributed 11.5cps in 2013 compared to 5.2cps in 2014.



LifeHCL has applied IAS 19 retrospectively in accordance with the transitional provisions of the standard. The surplus on post- retirement benefits will now be recognised in other comprehensive income (OCI) and no longer through the statement of comprehensive income. The result of this is that the EPS and HEPS for the comparative period have been restated to 164.8cps and 164.8cps from 169.7cps and 169.7cps, respectively.



The financial information on which this trading update is based has not been reviewed and reported on by the Company?s external auditors.



The Company expects to release its annual financial results for the year ended 30 September 2014 on SENS on or about 14 November 2014.



22-Jul-2014
(Official Notice)
Shareholders are advised that the Company will be increasing its shareholding in Max Healthcare Institute Limited ("MHC") to approximately 46.4% from its current shareholding of 26%. MHC, the leading private hospital provider in the Delhi-NCR region, is currently a subsidiary of Max India, one of India?s leading multi business corporates ("the transaction").



In January 2012, Life Healthcare invested Rs. 516.5 Cr, (R830 million) to acquire a 26% stake in MHC. MHC is one of India?s leading private hospital groups and operates 12 hospitals in North India, with a focus on high end tertiary and quaternary care. The current transaction will lead to a shareholding equalisation of both joint venture ("JV") partners (Life Healthcare and Max India) as envisaged in the original JV agreement. The International Finance Corporation ("IFC") holds the balance of the shareholding. India is an important market for the Company?s international growth strategy and the acquisition of the additional shares in MHC is in line with the Company?s growth strategy. The Company is confident in the quality of the asset in terms of infrastructure, clinicians and the ability of management to deliver on the business plans.



The transaction will be concluded through a 50% primary issue of new MHC shares and a 50% secondary acquisition of MHC shares held by Max India. The primary issue will be used to reduce debt and to fund further expansion. The expected date for the conclusion of the transaction is 31 August 2014. Post the transaction; both JV partners will have equal representation on the MHC Board. The transaction is subject to the following conditions precedent:

*definitive agreements being entered into between the two parties; and

*obtaining exchange control approval from the South African Reserve Bank and any other regulatory approval that may be required.



The consideration

The Company will invest up to a maximum of an additional Rs. 766 Cr in MHC (approximately R1, 350 million) at Rs.67.50 (approximately R11.91 per share). The exact amount is dependent on certain rights that the IFC has to participate in the primary issue and secondary sale. Life Healthcare will fund the transaction by raising additional debt.

14-May-2014
(Media Comment)
Business Day highlighted that Life Healthcare is advancing its position in the country's private hospital sector. The company, which has increased its hospital occupancy rates ahead of rivals in the past few years, continued to capitalise on South Africa's growing demand for private hospital services. Even if local competition is tight, Life Healthcare is increasingly looking beyond South Africa for growth. Last month the company bought a 80.7 percent stake in Polish private healthcare company Scanmed Multimedis for R427 million. In India, where it acquired a 26 percent stake in Max Healthcare Institute in 2011, revenues continued to grow.
13-May-2014
(C)
Revenue increased by 10.2% to R6.2 billion (R5.6 billion). Operating profit rose by 90.1% to R2.5 billion (R1.3 billion). Net attributable profit more than doubled by 140.5% to R1.8 billion (R754 million). In addition, headline earnings per share grew by 13.4% to 82.7cps (72.9cps).



Dividend

A gross interim ordinary dividend of 63cps has been declared.



Outlook

To meet increased demand for private hospital services, the group plans to add an additional 120 brownfield acute hospital beds in the next six months. In addition, the group has over 180 beds which are under construction which will be operational within the next 12 months, over 540 beds where health department license approval has been obtained but where local and municipal approvals are outstanding and over 1 100 beds where licence applications are pending. The group will continue to focus on driving operational efficiency through the management of cost of sales and the streamlining of administrative and IT processes and systems.



LifeHC will focus on bedding down its acquisition in Poland in the next six months and working with Max to improve its profitability. LifeHC's results for the full financial year ended 30 September 2014 are expected to show an improvement of more than 20% from those reported for the financial year ended 30 September 2013. This expected improvement is largely due to Life Healthcare's disinvestment of its 49.3% holding in JMH.
23-Apr-2014
(Official Notice)
Further to the trading statement released on the SENS on 7 March 2014, shareholders are advised that Life Healthcare?s earnings per share for the six months ended 31 March 2014 will be between 166 cents per share and 180 cents per share, compared to the restated earnings per share for the comparative period of 72.6 cents per share.



This is largely due to Life Healthcare?s disinvestment of its 49.3% shareholding in Joint Medical Holdings Limited. The directors believe that normalised earnings per share from continuing operations best reflect the performance of the Company and expect that normalised earnings per share will be 13% to 18% higher than the 71.3 cents per share reported in the comparative period. Excludes profit/loss on disposals of assets and businesses and associated costs.



The Group has applied IAS 19 retrospectively in accordance with the transitional provisions of the standard. The surplus/deficit on post-retirement benefits will now be recognised in other comprehensive income and no longer through the statement of comprehensive income. The result of this change is that the EPS and HEPS for the comparative period have been restated to 72.6 cents and 72.8 cents per share from 76.1 cents and 76.4 cents per share respectively. The financial information on which this trading statement is based has not been reviewed and reported on by the Company?s external auditors.

07-Mar-2014
(Official Notice)
Shareholders are advised that LifeHC's results for the six months ended 31 March 2014 are expected to show an improvement of more than 20% from those reported for the six months ended 31 March 2013. This expected improvement is largely due to LifeHC's disinvestment of its 49.3% shareholding in Joint Medical Holdings Ltd. However, as it is quite early in the reporting period, the company cannot, with reasonable certainty, quantify the extent by which its results for the six months ended 31 March 2014 will exceed the 20% range required by the JSE Ltd. Listings Requirements.



It is expected that a further trading statement for the six months ended 31 March 2014 will be issued later in the reporting period, and by no later than 25 April 2014.
21-Feb-2014
(Official Notice)
The company has accepted an offer to disinvest from its interest in JMH Holdings Ltd. ("JMH"). The transaction became substantially unconditional on 17 February 2014 and the proceeds of the transaction will be received by the company on 28 February 2014.



After consideration of the cash position, the directors accordingly approved and declared a special gross cash dividend of 100,0 cents per ordinary share out of income reserves on 20 February 2014.



As no secondary tax on companies' credits are available, the dividend will be subject to dividend withholding tax at a rate of 15%, which will result in a net dividend of 85.0 cents per share to those shareholders who are not exempt in terms of section 64F of the Income Tax Act.



The company's tax reference number is 9387/307/15/1. The issued share capital at the declaration date is 1 042 209 750 ordinary shares.



In compliance with the requirements of the JSE Ltd., the following dates are applicable:

Last day to trade cum the dividend -- Friday, 7 March 2014

Trading commences ex the dividend -- Monday, 10 March 2014

Record date -- Friday, 14 March 2014

Payment date -- Monday, 17 March 2014



Share certificates may not be dematerialised or rematerialised between Monday, 10 March 2014 and Friday, 14 March 2014, both days inclusive.
14-Feb-2014
(Official Notice)
Further to the SENS published on 14 November 2013, shareholders are advised that Michael Flemming, the Company's CEO will now retire on 31 March 2014. Andr? Meyer who will join the organisation on 1 March 2014 will be appointed as CEO with effect from 1 April 2014. Mr Flemming's services will be available to the Company on a consultancy and advisory basis from 1 April 2014 to 30 June 2014.
30-Jan-2014
(Official Notice)
At the 9th annual general meeting of the shareholders of Life Healthcare held on 30 January 2014, all the ordinary and special resolutions proposed at the meeting were approved by the requisite majority of votes.



The special resolution will be lodged for registration with the Companies and Intellectual Property Commission in due course.



Shareholders are also advised that TS Munday has retired from the board of Life Healthcare with effect from 30 January 2014. Peter Golesworthy will replace Mr Munday as the lead independent non-executive director with effect from 31 January 2014.
13-Dec-2013
(Official Notice)
Shareholders are advised that the consolidated condensed financial results contained in the notice of annual general meeting will be distributed to shareholders on Friday, 13 December 2013 and contain no modifications to the audited results which were published on SENS on Thursday, 14 November 2013. The integrated annual report and the audited financial statements will be available on the LifeHC website at www.lifehealthcare.co.za on Friday, 13 December 2013.



Notice of the annual general meeting

Notice is given that the annual general meeting of the Company will be held at LifeHC's offices in the St George's meeting room, Oxford Manor, 21 Chaplin Road, Illovo, Johannesburg on Thursday, 30 January 2014 at 15h30 to transact the business as stated in the annual general meeting notice.
06-Dec-2013
(Official Notice)
The announced that Royden Vice has been appointed as an independent non-executive director of the company with effect from 1 January 2014.
14-Nov-2013
(C)
Revenue grew 8.3% to R11.8 billion (R10.9 billion) whilst operating profit was 16% higher at R2.9 billion (R2.5 billion). profit attributable to equity holders jumped 17.7% to R1.8 billion (R1.5 billion). Furthermore, headline earnings per share rose 20.6% to 169.7 cents per ordinary share (140.7cents per ordinary share).



Cash dividend declaration

The directors approved and declared a final gross cash dividend of 72 cents per ordinary share (60 cents per ordinary share) out of income reserves on 14 November 2013.



Outlook

The Group will continue to focus on its growth objectives in South Africa by adding additional beds through brownfield expansion, new greenfield facilities and mental healthcare. Life Healthcare has 325 new beds which are expected to be operational within the next 12 to 15 months, over 500 beds where Health department licence approval has been obtained but where local and municipal approvals are outstanding and over 1 100 beds where licence applications are pending. Max will continue to increase the number of operational beds as more beds are opened in its new hospitals. The Group will continue to look for investment opportunities in its selected emerging markets.



The focus to drive operational efficiencies in South Africa through optimising cost of sales and procurement, streamlined administrative processes, the re-engineering of certain IT systems, and improving hospital occupancies to enable the leveraging of the fixed cost base, remains.



The quality management programme of the Group is a comprehensive, consistently applied and measured programme which benchmarks clinical interventions against international best practise with the aim of enhancing patient outcomes. In addition the Life Healthcare recognises the shortage of healthcare skills and will continue to invest heavily in the training of doctors, nurses and pharmacists. The proposed Competition Commission market inquiry into the healthcare sector is expected to start in 2014. The inquiry represents an opportunity to factually demonstrate what the real cost drivers of the healthcare industry are as well as proposing structural changes to make the industry more efficient and affordable and we will participate fully.
14-Nov-2013
(Official Notice)
The board announced that Professor Marian Jacobs has been appointed as an independent non-executive director of the Company with effect from 1 January 2014.
14-Nov-2013
(Official Notice)
The board of directors of Life Healthcare announced that Michael Flemming, the Company's CEO intends retiring on 30 June 2014.



To ensure a smooth transition when Michael retires, the board is announced the appointment of Andre Meyer as CEO elect, Andre will join the Company on 1 March 2014 and will succeed Michael on his retirement. Andre is currently the CEO of Medscheme having been appointed in April 2003. Prior to that, he was the managing director of the Healthcare division within Alexander Forbes.
17-Oct-2013
(Official Notice)
Life Healthcare is currently finalising its results for the year ended 30 September 2013 (the period), which should be released on SENS on or about 15 November 2013. Shareholders are advised that headline earnings per share for the period are likely to be between 18% and 22% higher and earnings per share for the period are likely to be between 15% and 19% higher than that reported for the year ended 30 September 2012. The financial information on which this trading statement is based has not been reviewed and reported on by the Company's external auditors.
14-May-2013
(C)
Revenue for the interim period increased by 7% to R5.6 billion (2012: R5.3 billion). Operating profit jumped by 12.7% to R1.4 billion (2012: R1.2 billion), while profit after tax attributable to ordinary equity holders of the parent was 14.5% higher at R790 million (2012: R690 million). Furthermore, headline earnings per share shot up by 19.8% to 76.4cps (2012: 63.8cps).



Cash dividend

The directors approved an interim cash dividend of 54cps (2012: 45cps) amounting to R562 793 265 (2012: R468 994 388) out of income reserves.



Outlook

Despite a tougher economic environment the Group expects to see increased demand for hospital services and the additional growth in medical cases is expected to continue. The Group plans to add an additional 1 000 acute hospital, mental health and acute rehabilitation beds in South Africa over the next three to four years.



The Group will continue to focus on driving operational efficiency through the management of cost of sales, streamlining administrative processes, and the completion of the Impilo modules. The underlying fundamentals in India for private hospital services are strong and the Group is confident that Max Healthcare, India will continue to show improved revenues and EBITDA margins. The Group will continue to look for additional growth opportunities in India and Africa.
13-May-2013
(Official Notice)
Shareholders are referred to the announcement released on SENS on 15 November 2012 in respect of the retirement of Roger James Hogarth as an executive director from the board of LifeHC with effect from 31 May 2013. In compliance with the JSE Limited Listings Requirements, the board of directors is pleased to announce the appointment of Pieter van der Westhuizen CA(SA)as an executive director and chief financial officer of the Company with effect from 1 June 2013.
25-Apr-2013
(Media Comment)
The Financial Mail wrote that LifeHC is bucking the trend in its expansion beyond Africa. The group prefers developing markets, unlike its rivals who are in the UK and Switzerland. India and Turkey are high on LifeHC's expansion targets, as well as Poland. In Africa, LifeHC's GM for strategy and development, Jonathan Lowick, says the strategy is to purchase majority stakes in existing hospitals and then grow operations with a local partner.
21-Feb-2013
(Official Notice)
Ketan (Ketso) Gordhan has resigned as a non-executive director of LifeHC with effect from 22 February 2013 to enable him to fulfill his extensive work commitments. Ketso has been a board member since November 2010.
14-Feb-2013
(Official Notice)
Further to the announcement released on SENS on 12 December 2012 advising of the appointment of Mustaq Brey as the acting chairman of the board of directors of LifeHC ("the board"), the board announced that Mustaq Brey has been appointed the permanent chairman of the board with immediate effect. In line with the King Report on Corporate Governance in South Africa (2009), Trevor Munday will continue in his role as lead independent non-executive director.
01-Feb-2013
(Official Notice)
At the 8th annual general meeting of the shareholders of LifeHC held on 31 January 2013, all the ordinary and special resolutions proposed at the meeting were approved by the requisite majority of votes, save for special resolution number four, Replacement of the Memorandum of Incorporation which received 74.55872% votes in favour of the resolution.
20-Dec-2012
(Official Notice)
Shareholders were advised that the consolidated condensed financial results contained in the notice of annual general meeting and abridged shareholder report will be distributed to shareholders on Thursday, 20 December 2012 and contain no modifications to the audited results which were published on SENS on Friday, 16 November 2012. The integrated annual report and the audited financial statements will be available on the LifeHC website at www.lifehealthcare.co.za on Thursday, 20 December 2012.



Notice of the annual general meeting

Notice is hereby given that the annual general meeting of the company will be held at The Wanderers Club, 21 North Street, Illovo, Johannesburg on Thursday, 31 January 2013 at 15h30 to transact the business as stated in the annual general meeting notice (including resolutions seeking a specific authority to issue shares for cash and the approval of LifeHC's new Memorandum of Incorporation) forming part of the consolidated condensed financial results and abridged shareholder report.



Salient dates

The notice of the company's annual general meeting has been sent to its shareholders who were recorded as such in the company's securities register on 7 December 2012 being the notice record date set by the board of the company used to determine which shareholders are entitled to receive notice of the annual general meeting.



Salient dates

*Record date to determine which shareholders are entitled to receive the notice of annual general meeting -- 7 December 2012

*Last day to trade in order to be eligible to attend and vote at the annual general meeting -- 18 January 2013

*Record date to determine which shareholders are entitled to attend and vote at the annual general meeting -- 25 January 2013

*Forms of proxy for the annual general meeting to be 29 January 2013 lodged by 15h30
12-Dec-2012
(Official Notice)
Shareholders were referred to the announcement released on SENS on 28 November 2012 advising of the passing of the chairman of the board, Professor Jakes Gerwel. The board of directors? wish to advise that Mustaq Brey has been appointed as acting chairman of the board with immediate effect. He has also been appointed as a member and chairman of the nominations committee for the duration of his tenure as acting chairman of the board. The board will commence with a process to identify and appoint a permanent chairman of the board. Mr Brey will serve as acting chairman until the appointment of a permanent chairman is confirmed.
28-Nov-2012
(Official Notice)
It is with great sadness that the board of Life Healthcare advises of the death of Professor Jakes Gerwel. Professor Gerwel passed away in hospital in the early hours of this morning.
19-Nov-2012
(Media Comment)
According to Business Day, Life was planning to open 1 000 more beds in the next four years, anticipating increased demand from a growing sick population. Micheal Flemming, CEO said that the country still has a lot of sick people and that the demand for care and length of stay in hospital has increased. Avior Research analyst, Matthew Menezes said the private hospital group's performance was solid and Aeon Investment Management analyst, Dean Marks, concurred that the company had done reasonably well in a difficult environment.
16-Nov-2012
(C)
Revenue increased by 11.5% to R10.9 billion (R9.8 billion). Operating profit was up 17% to R2.5 billion (R2.2 billion). Net attributable profit rose 16.2% to R1.5 billion (R1.3 billion). In addition, headline earnings per share grew 17.7% to 140.7cps (119.5cps).



Dividend

A gross final ordinary dividend of 60cps has been declared.



Outlook

The group expects to see continued increased demand for hospital services due to the high incidence of disease together with a growing medical aid population, the impact of aging and preferred network arrangements. The group has plans to add an additional 1 000 beds over the next three to four years to cater for this additional demand and has a combination of licence approvals and licence applications pending for over 550 beds. R752 million has been allocated for capital projects for the 2013 financial year. The group will continue to look for growth opportunities in India and the east and west coasts of Africa. The group continues to focus on driving efficiencies to ensure services remain affordable and to expand access to its services.
15-Nov-2012
(Official Notice)
Roger James Hogarth will retire as an executive director from the board of Life Healthcare Group Holdings Limited with effect from 31 May 2013.
11-May-2012
(C)
Revenue increased by 11.7% to R5.3 billion (R4.7 billion). Operating profit rose by 22.4% to R1.2 billion (R987 million). Net attributable profit was up by 25% to R690 million (R552 million). In addition, headline earnings per share grew by 21.3% to 63.8c (52.6cps).



Dividend

An interim ordinary dividend of 45cps has been declared.



Outlook

Subject to the current economic conditions prevailing for the rest of the financial year, the group expects continued growth in earnings.



Growth

The group will continue to focus on its growth objectives in South Africa by adding additional beds through brownfield expansion and mental healthcare, including the 80 bed Life Poortview mental health facility in Gauteng. LifeHC will assist Max Healthcare to improve its business operations.



Efficiency

The group will continue to focus on driving operational efficiencies in South Africa through; cost of sales, procurement, streamlined administrative processes; the re-engineering of certain IT systems and improving hospital occupancies to enable the leveraging of the fixed cost base.



Sustainability

The group will continue to focus on and expand its quality management programme which is a comprehensive, consistently applied and measured programme which benchmarks clinical interventions against international best practice with the aim of enhancing patient outcomes. In addition the group recognises the shortage of healthcare skills and will continue to invest heavily in the training of doctors, nurses and pharmacists. In connection with the development of healthcare policy and proposed healthcare reforms, the group will continue to actively engage with the South African government.
16-Apr-2012
(Official Notice)
Life is currently finalising its results for the six months ended 31 March 2012, which should be released on SENS on or about 11 May 2012. In this regard, shareholders were advised that earnings per share and headline earnings per share are likely to be between 20% and 25% higher than that reported for the six months ended 31 March 2011.
16-Jan-2012
(Official Notice)
Further to the SENS announcement published on 11 October 2011, Life advised shareholders that the company has signed definitive agreements with Max Healthcare Institute Ltd ("MHC") and Max India Ltd ("Max India") for the subscription of 26% of the post-issue share capital of MHC subject to the fulfilment of certain conditions precedent. The subscription price is IAR516.5 CR Rupees. Life will provide pro-rata guarantees for its proportionate share of the debts of MHC currently guaranteed by Max India. MHC is a leading private hospital provider in the Delhi-NCR (National Capital Region) and is a subsidiary of Max India, one of India's leading multi business corporates.
16-Nov-2011
(C)
Revenue increased by 11.7% to R9 812 million (September 2010: R8 786 million), while operating profit was rose by 16.4% to R2 173 million (September 2010: R1 867 million). Profit attributable to ordinary shareholders grew by 93.8% to R1 287 million (September 2010: R664 million). Headline earnings per share increased by 88.2% to 119.5cps (September 2010: 63.5cps).



Distribution

The board has approved a distribution to shareholders of 54cps consisting of a dividend of 18cps and a distribution of capital out of share premium of 36cps.



Outlook

Growth

The group will continue to focus on its growth objectives in South Africa:

*Developing the breadth and depth of the Group?s existing hospital network, through brownfield expansions

*Expanding our coverage and penetration in the South African market through acquisitions, new builds and new lines of business.



The group aims to add on an additional 300 beds in 2012.



Efficiency

The group will continue to focus on driving operational efficiencies, cost of sales procurement and management and increasing hospital occupancies to enable the leveraging of the fixed cost base.



Sustainability

The group will continue to focus on and expand it's quality management programme which is a comprehensive, consistently applied and measured programme which benchmarks clinical interventions against international best practice with the aim of enhancing patient outcomes. In addition the group recognises the shortage of healthcare skills and will continue to invest heavily in the training of doctors, nurses and pharmacists. In connection with the development of healthcare policy and proposed healthcare reforms the group will continue to actively engage with the South African government.



31-Oct-2011
(Official Notice)
Shareholders are referred to the SENS announcement dated 29 July 2011 whereby shareholders were advised that the company's results for the year ended 30 September 2011 were expected to show an improvement of more than 20% from those reported for the year ended 30 September 2010 ("comparative period").



Life Healthcare is currently finalising its results for the year ended 30 September 2011, which should be released on SENS on 17 November 2011. In this regard, shareholders are advised that earnings per share and headline earnings per share are expected to be between 85% and 95% higher than the comparative period.



This is largely attributable to the costs incurred relating to the company's Initial Public Offering in June 2010 including Secondary Tax on Companies and lower net finance costs following the refinancing of debt in May 2010. The forecast financial information on which this trading statement is based has not been reviewed and reported on by the external company's auditors.
11-Oct-2011
(Official Notice)
Shareholders were advised that the company has entered into a non binding term sheet with Max Healthcare Institute Ltd ("MHC") for the acquisition of 26% of the post-issue share capital of MHC ("the proposed acquisition"). MHC, the leading private hospital provider in the Delhi- NCR region, is a subsidiary of Max India, one of India's leading multi business corporates.



Terms of the proposed acquisition

The proposed acquisition is subject to the following conditions precedent:

* definitive agreements being entered into between the two parties;

* a due diligence exercise to be performed by the company;

* obtaining exchange control approval from the South African Reserve Bank and any other regulatory approval that may be required; and

* approval by the boards of the company and MHC.



The consideration

The proposed acquisition price is Rs 516.5 crore (approximately R850 million) which will be settled in cash. LifeHC will, subject to the consent of its lenders, provide pro-rata guarantees for its proportionate share of the debts of MHC currently guaranteed by Max India.
29-Jul-2011
(Official Notice)
The group's results for the year ending 30 September 2011 are expected to show an improvement of more than 20% from those reported for the year ended 30 September 2010. This arises due to, inter alia, costs associated with the listing of the company in the 2010 financial year, the most significant of which was the Secondary Tax on Companies charge. Accordingly, the group is required to issue a trading statement. Life Healthcare cannot at this stage with reasonable certainty, quantify the extent of its results for the year ending 30 September 2011.



A trading statement for the year ending 30 September 2011 will be issued later in the reporting period, which should be before the end of October 2011. The forecast financial information on which this trading update is based has not been reviewed and reported on by the group's external auditors.
26-Jul-2011
(Official Notice)
In compliance with the JSE Limited Listings Requirements, the following information is disclosed: Paul Boynton resigned as Garth Solomon's alternate on the board of Life Healthcare Group Holdings Limited with effect from 1 March 2011.

03-Jun-2011
(Official Notice)
Shareholders were advised of the following: OMLACSA has notified the company that it has decreased its holding in the company by 5%, reducing its holding in the company from 154 453 475 to 103 178 765. Accordingly, OMLACSA's holding represents 9.99% of the voting rights in the company.
11-May-2011
(Media Comment)
Business Report highlighted that despite continued concerns about affordability of the private health services, Life Healthcare recorded double-digit growth in earnings in the six months to March as volumes were boosted by an increase in the number of days spent by patients in hospitals. Michael Flemming, the managing director at Life Healthcare said the increase in the number of paid patient days exceeded expectations.Mr Flemming added that the network arrangements with the scheme had been successful as they helped to attract new people who were previously uninsured and to keep people in the system who might have otherwise left because of private health care costs.
10-May-2011
(C)
LifeHC's maiden interim results showed revenue of R4.7 billion and operating profit of R987 million. Net attributable profit amounted to R552 million. In addition, headline earnings on a per share basis of 52.6cps was recorded.



Dividend

An interim cash distribution of 31cps on 9 May 2011 was declared by way of a dividend of 11cps and a capital reduction out of share premium of 20cps.



Outlook

LifeHC is investing in future bed capacity across it's acute hospitals, mental health and acute rehabilitation facilities to meet higher demand due to the increasing disease burden, ageing population, the increase in private insured lives and the preferred network arrangements negotiated with the funders. LifeHC will continue to focus on improving it's occupancy and efficiency and cost savings programmes to ensure continued real growth in normalised earnings.
11-Apr-2011
(Official Notice)
LifeHC is currently finalising its results for the six months ended 31 March 2011, which should be released on SENS before 10 May 2011. In this regard, shareholders are advised that earnings per share and headline earnings per share are likely to be between 30% and 40% higher than that reported for the six months ended 31 March 2010. This is largely attributable to growth in activities, operational efficiencies, expenses of a non-recurring nature in 2010 as well as lower net financing costs as a result of the refinancing of debt prior to the IPO in June 2010.
27-Jan-2011
(Official Notice)
At the 6th annual general meeting of the shareholders of Life Healthcare held today, 27 January 2011, all the ordinary and special resolutions proposed at the meeting were approved by the requisite majority of votes. The special resolution will be lodged for registration with the Companies and Intellectual Property Registration Office in due course. Shareholders are also advised that YZ Cuba and Dr. JPF Dalmeyer have retired from the board of Life Healthcare, with effect from today.

17 Dec 2010 15:12:12
(Official Notice)
Lawrie Zev Brozin has resigned as Mustaq Brey's alternate on the board of LifeHC with effect from 17 December 2010. Craig Warwick John Lyons has resigned as Yolanda Cuba's alternate on the board of LifeHC with effect from 17 December 2010.
15 Dec 2010 12:00:34
(Official Notice)
Shareholders are advised that the annual financial statements will be distributed to shareholders on or about 20 December 2010 and contain no modifications to the audited results which were published on SENS on 30 November 2010. The annual report will be available on the company's website, www.lifehealthcare.co.za.



Notice of the annual general meeting

Notice was hereby given that the sixth annual general meeting of LifeHC shareholders will be held at the Wanderers Club, 21 North Street, Illovo, Johannesburg on Thursday 27 January 2011 at 13h30 to transact the business as stated in the annual general meeting notice forming part of the annual financial statements.
01 Dec 2010 14:24:15
(Official Notice)
Ketan (Ketso) Gordhan, Joel Khathutshelo Netshitenzhe and Francine-Anne du Plessis have been appointed as non-executive directors to the board of Life Healthcare Group Holdings Ltd with effect from 30 November 2010.
30 Nov 2010 13:46:00
(C)
Life Healthcare in its maiden final results posted revenue of R8 786 million, while operating profit was recorded at R1 867 million. Profit attributable to ordinary shareholders was recorded at R664 million, and normalised earnings per share was at 92.7cps.



Dividend

The board of directors has reviewed the dividend policy and has approved a dividend cover of between 1.75 and 2.75 times. The directors have declared a final cash dividend of 29cps payable to shareholders.



Outlook

Life Healthcare is confident that the demand for private healthcare in South Africa will continue due to the increasing disease burden and ageing medical aid population. Taking into consideration the proposed growth in hospital capacity as well as the business benefits of our efficiency programmes, Life Healthcare is optimistic that historical growth rates will be maintained.
13 Sep 2010 11:34:38
(Media Comment)
The Sunday Times Business Times noted that newly listed LifeHC will replace Raubex Group Ltd ("Raubex") in the JSE mid-cap index. Raubex's market value has declined by almost 20% in 2010.
23 Aug 2010 11:31:20
(Official Notice)
Eutychus Wahome Mbuthia has resigned as a non-executive director from the board of LifeHC with effect from 23 August 2010. Andrew Guthrie Aitken has resigned as Eutychus Mbuthia's alternate on the board of LifeHC with effect from 23 August 2010.
20 Aug 2010 17:22:44
(Official Notice)
Neo Violet Mokhesi (formerly Sowazi) has resigned as a non-executive director from the board with effect from 20 August 2010.
22 Jul 2010 11:24:21
(Official Notice)
Life shareholders are referred to the condensed consolidated interim financial information for the six months ended 31 March 2010 and dividend policy contained in the pre-listing statement dated 18 May 2010 and are hereby advised that the directors of Life confirmed that they intend declaring an annual dividend 2 times to 2.25 times covered by headline earnings, payable in approximately equal interim and final dividends. The directors have, following the completion of the listing on the main board of the JSE Limited, resolved to declare an interim dividend of 23 cents per share for the six month period ended 31 March 2010. Future interim dividends will be considered with the announcement of the interim results to March each year and a final dividend will be considered with the release of the annual results for the year ended September.



The salient dates will be as follows:

*Last day to trade "cum" the dividend on Thursday, 5 August 2010.

*Shares commence trading "ex" dividend on Friday, 6 August 2010.

*Record date on Friday, 13 August 2010.

*Payment date on Monday, 16 August 2010.

*Share certificates may not be dematerialised or rematerialised between Friday, 6 August 2010 and Friday, 13 August 2010, both days inclusive.
12 Jul 2010 09:58:32
(Official Notice)
Life Healthcare Group Holdings Ltd (the "company") announced that, in connection with the initial public offering of ordinary shares in the company (the `global offer`), Rand Merchant Bank, a division of FirstRand Bank Ltd, as stabilisation manager, exercised in part the over-allotment option in respect of 33 175 458 ordinary shares in the company (the `optional sale shares`) on 9 July 2010. Including the optional sale shares, the total size of the global offer is R5.233 billion (387 595 738 ordinary shares).
11 Jun 2010 09:32:41
(Media Comment)
LifeHC listed successfully on the JSE on Thursday, 10 June 2010, and as expected the shares which were sold to selected South African and international investors and were placed at R13.50. Though there was hardly any movement in the share price throughout the day, it did hit a R13.95 at some stage. Life Healthcare placed about R5.2 billion and approximately 40 percent was subscribed for by foreign investors, which the company deemed as a major vote of confidence, though analysts were not convinced. Mark Ansley, a portfolio manager at Cadiz was quoted as saying "it has been a pretty unexciting listing". There has not been much of a push in the share price which usually happens in the beginning. Initially the company said the shares would be placed at between R14.50 and R17.00, giving the shares to be placed a value of more than R7 billion, but this was revised down after the listing road shows.
26-Apr-2017
(X)
LHC's core business is the provision of acute private hospital care. The acute care hospitals are complemented by mental health, acute rehabilitation, renal dialysis and the healthcare services business consisting of Life Esidimeni and Life Occupational Health. LHC's business is organised into three divisions:



*Hospital Division: LHC's acute hospitals extend over seven of South Africa's nine provinces and Botswana. These facilities consist of 50 acute hospitals with 8 067 registered beds and range from high technology, multi-disciplinary hospitals to community hospitals, same day surgical centres and dedicated niche facilities. Acute rehabilitation complements the services offered by the acute hospitals and offers acute, outcomes driven physical and cognitive rehabilitation for adult and paediatric patients. There are seven facilities with 319 registered beds. LHC is a leading provider of private mental health through six facilities in Gauteng, Kwazulu-Natal and the Eastern Cape with 386 registered beds. LHC renal dialysis is a specialised service dedicated to treating patients on acute and chronic renal dialysis. LHC has 22 units with 281 stations.



*Healthcare services Division: includes Life Esidimeni, Life Occupational Health and Careways. Life Esidimeni is the largest and longest running public private partnership in the South African healthcare sector. Life Esidimeni consists of 2 424 beds providing long term clinical care to chronically ill patients. Life Employeel Health Solutions operates 371 on-site, off-site and mobile clinics to approximately 419 659 employees. The acquisition of the employee wellness entity, Careways, allows the Group to offer occupational health and employee wellness as an integrated service for corporate customers. Careways operates 79 on-site clinics and covers 195 195 lives.



*International Division: comprises LHC's acquisition of 45.95% of Max Healthcare Institute (MHC) and Scanmed Multimedis S.A.(Scanmed) a private healthcare service provider in Poland. Scanmed consists of 624 beds, seven inpatient cardiology centres and 40 medical centres. MHC has 12 hospitals with 2 384 beds.



Send e-mail to for any enquiries or see Contact Details for phone numbers
Home   •   Terms & conditions   •   PAIA   •   Privacy Policy   •   Security Notice   •   Contact Details
Market Statistics are calculated by Sharenet and are therefore not the official JSE Market Statistics. The calculation/derivation may include underlying JSE data.
© 2017 SHARENET (PTY) Ltd, Cape Town, South Africa
Best in 800x600 with IE6 or Mozilla Firefox